Subramanian aruna (11 risultati)

Hardcover. Condizione: Very Good. No Jacket. Former library book; May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Condizione: good. This is a pre-loved book that shows moderate signs of wear from previous reading. You may notice creases, edge wear, or a cracked spine, but it remains in solid, readable condition. Please note: -May include library or rental stickers, stamps, or markings. -Supplemental materials e.g., CDs, access codes, inserts are not guaranteed. -Box sets may not come with the original outer box. If it does, the box will not be in perfect condition. Your satisfaction is our top priority! If you have any questions or concerns about your order, please don't hesitate to reach out. Thank you for shopping with us and supporting small businessâ"happy reading.…

Hardcover. Condizione: Very Good. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Hardcover. Condizione: New.

Hardcover. Condizione: Brand New. 1st edition. 283 pages. 9.25x6.25x0.75 inches. In Stock.

Hardcover. Condizione: Brand New. 240 pages. 9.29x6.30x0.83 inches. In Stock.

Hardback. Condizione: New. New copy - Usually dispatched within 4 working days.

Condizione: new. Questo è un articolo print on demand.

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks. The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets. The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics. 240 pp. Englisch.…

Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Transplant and oncology patients present a challenge to the infectious disease specialist because many of the entities that infect them are hard to diagnose. Chemotherapy may further complicate the situation, since it may contraindicate a biopsy or interfere with antibiotic therapy. This issue of Infectious Disease Clinics provides specific information on several entities with the purpose of helping physicians to best treat these difficult infections. …

Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks. The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets. The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics.…